In IMpassion-130 trial, PD-L1 expression was assessed using the SP142 PD-L1 immunohistochemical assay (Ventana Medical Systems), while PD-L1 positivity was defined as the presence of stained tumour-infiltrating immune cells covering ≥ 1% of the tumour area [22]. This evidence concerns the gene CD274 and neoplasm.